Skip to content

Effect of Remimazolam and Propofol on Postoperative Delirium

Effect of Remimazolam and Propofol on Postoperative Delirium in Elderly Patients Undergoing Hip and Knee Surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05514405
Enrollment
82
Registered
2022-08-24
Start date
2022-08-01
Completion date
2026-09-30
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femur Fracture, Hip Fractures, Knee Osteoarthritis

Brief summary

Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, hemodynamic stability compared to propofol gives clinicians preference to use for geriatric anesthesia. However, the study on the effect of remimazolam compared to propofol on postoperative delirium have not been carried out. The purpose of the study is to compare the incidence of postoperative delirium and recovery profile in elderly patients undergoing orthopedic surgery using either remimazolam or propofol.

Interventions

Remimazolam is continuously infused based on bispectral index (within 40-60).

DRUGPropofol

Propofol is continuously infused based on bispectral index (within 40-60).

Sponsors

Inje University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* elderly patients undergoing hip or knee arthroplasty under general anesthesia. * body mass index \>30 kg/m2

Exclusion criteria

* moderate to severe liver dysfunction * moderate to severe renal dysfunction * unable to extubate in the operation room after operation * benzodiazepine dependence * sensitivity to anesthetic drugs used for study (Benzodiazepines, Propofol, Remifentanil, Fentanyl citrate, Rocuronium bromide, Sugammadex, Flumazenil) * acute angle glaucoma * received (benzodiazepine, antianxiety drugs, antidepressant, antipsychotic drugs) within 24 hours. * acute psychotic depression * history stroke or cerebrovascular disease

Design outcomes

Primary

MeasureTime frameDescription
Incidence of delirium 3 days after the end of operationUpto 3 days after surgerydelirium is evaluated preoperatively and 3 days after surgery using Mini-Mental State Examination

Secondary

MeasureTime frameDescription
quality of recovery (QoR-15) 3 days after the end of the operationUpto 3 days after surgeryQoR-15 survey is performed preoperatively and 3 days after surgery.

Countries

South Korea

Contacts

CONTACTIn-Jung Jun, MD PhD
christine17@hanmail.net82-10-9312-0162
STUDY_CHAIRIn-Jung Jun, MD PhD

Inje University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026